Share
5,681 Posts.
lightbulb Created with Sketch. 1742
clock Created with Sketch. 31/07/20
17:13
Share
Originally posted by needle:
↑
Sight of relief, these costs for GBM are very modest and importantly have been made, last quarter. Still nearly 9m despite one off payments made last quarter. In particular, the cashflows reported in this Appendix 4C include milestone payments associated with the completion of the Cantrixil phase I study, as well as one-off costs for the set-up of GBM AGILE. Accordingly, it is difficult to draw inferences as to the anticipated expenditure in FY2021"
Expand
It mentions having made one-off costs for the setup of AGILE. No info about future costs. The report is deliberately obscure about future spending IMHO, no doubt due to it also stating they are pursuing funding options. Just being pedantic.
